Acasti Pharma Inc - Class A ACST Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$3.30 up $0.19, 6.11% on Oct 24
Last price · Previous close $3.11
- Market cap
- $31.02MAt the last price
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$3.30up $0.19, 6.11%Thu, Oct 24 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$3.11Oct 7
- Volume12.26KOct 7 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume39.43KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the last price. Total return includes reinvested dividends.Price change only, without dividends.
| Period | ACST |
|---|---|
| Short term | |
| 1M | ACST: up 28.9% |
| 3M | ACST: up 12.2% |
| YTD | ACST: up 14.2% |
| 1Y | ACST: up 37.5% |
| Long term | |
| 3Y | ACST: down 67.3% −31.1% a year |
| 5Y | ACST: down 96.8% −49.9% a year |
| 10Y | ACST: down 98.7% −35.5% a year |
$10,000 invested in ACST 10 years ago (Oct 17, 2014) would be worth about $125 as of , with dividends reinvested.
| Period | ACST |
|---|---|
| Short term | |
| 1M | ACST: up 28.9% |
| 3M | ACST: up 12.2% |
| YTD | ACST: up 14.2% |
| 1Y | ACST: up 37.5% |
| Long term | |
| 3Y | ACST: down 67.3% −31.1% a year |
| 5Y | ACST: down 96.8% −49.9% a year |
| 10Y | ACST: down 98.7% −35.5% a year |
$10,000 invested in ACST 10 years ago (Oct 17, 2014) would be worth about $125 as of , not counting dividends.
All-time high
$1,953.60
Closing high on . Now 99.8% below that record.
Split-adjusted daily closes since May 6, 2011.
Stock splits
3
Latest: 1-for-6 on . Share counts adjust after each split.
All 3 splits
- 1-for-6
- 1-for-8
- 1-for-10
Valuation
The last price compared with the last 12 months of reported results (the four quarters to Jun 30, 2024). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
Other valuation measures
- Price-to-bookPausedBook value as of Jun 30, 2024
See the note under the price. - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - −30.95%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $11.61MAt the last price
What it would cost to buy the whole business: the market cap at the last price, plus debt, minus cash and short-term investments from the Jun 30, 2024 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own ACST DCF in Excel. Value Acasti Pharma with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q1 FY25, the quarter ended Jun 30, 2024. “Last 12 months” means the four quarters from Jul 1, 2023 to Jun 30, 2024, and balance-sheet figures are as of Jun 30, 2024.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$11.45M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q2 FY23 (Sep 30, 2022) | $0.00 | −$4.93M | Paused See the note under the price. |
| Q3 FY23 (Dec 31, 2022) | $0.00 | −$3.89M | Paused See the note under the price. |
| Q4 FY23 (Mar 31, 2023) | $0.00 | −$29.09M | Paused See the note under the price. |
| Q1 FY24 (Jun 30, 2023) | $0.00 | −$4.02M | Paused See the note under the price. |
| Q2 FY24 (Sep 30, 2023) | $0.00 | −$3.27M | Paused See the note under the price. |
| Q3 FY24 (Dec 31, 2023) | $0.00 | −$2.39M | Paused See the note under the price. |
| Q4 FY24 (Mar 31, 2024) | $0.00 | −$3.17M | Paused See the note under the price. |
| Q1 FY25 (Jun 30, 2024) | $0.00 | −$2.62M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Mar 31, 2021) | $196.00K | −$19.68M | Paused See the note under the price. |
| FY22 (Mar 31, 2022) | $0.00 | −$9.82M | Paused See the note under the price. |
| FY23 (Mar 31, 2023) | $0.00 | −$42.43M | Paused See the note under the price. |
| FY24 (Mar 31, 2024) | $0.00 | −$12.85M | Paused See the note under the price. |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$9.60MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$9.69MLast 12 months
- Capital spending$89.00KLast 12 months
Shareholder returns
- $7.36MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $19.41MAs of Jun 30, 2024
Cash plus short- and long-term marketable securities on the Jun 30, 2024 balance sheet.
- Total debt$0.00As of Jun 30, 2024
- Net cash$19.41MAs of Jun 30, 2024
- Book value per sharePausedAs of Jun 30, 2024
See the note under the price. - 7.86As of Jun 30, 2024
Current assets divided by current liabilities on the Jun 30, 2024 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2024
Total debt divided by shareholders’ equity on the Jun 30, 2024 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −18.1%Last 12 months
Over the last 12 months, Acasti Pharma lost money: its net loss was 18.1% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −15.4%Last 12 months
Over the last 12 months, Acasti Pharma’s net loss was 15.4% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Acasti Pharma Inc - Class A
Acasti Pharma Inc. (Acasti) is engaged in developing a product portfolio of long-chain omega-3 phospholipids. Acasti is a majority owned subsidiary of Neptune Technologies and Bioressources Inc. (Neptune). The Company has one operating segment: the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The Company's product portfolio includes concentrated phospholipids which functionalize eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Acasti is the producer of anti-dyslipidemic prescription drugs (CaPre), medical foods (Onemia) and over-the-counter (OTC) products (Vectos). During the fiscal year ended February 28, 2011 (fiscal 2011), the Company has completed the development and launched medical food, Onemia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Quebec, Canada
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
ACST news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ACST stock FAQ
What is ACST stock’s price today?
Acasti Pharma (ACST) traded at $3.30 as of , up $0.19 (6.11%) from the previous close of $3.11.
If you invested $1,000 in ACST 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ACST on would be worth about $13 as of , a total return of −98.7%. The same $1,000 would be worth $32 if invested five years ago and $1,375 if invested one year ago. Past performance doesn’t predict future returns.
What is Acasti Pharma’s market cap?
Acasti Pharma’s market capitalization is about $31.0 million. That’s Tiingo’s daily market cap for , scaled to the last price of $3.30 on (how market cap works).
Does ACST pay a dividend?
Acasti Pharma hasn’t paid a dividend in the last twelve months.
What is ACST’s all-time high?
ACST’s highest closing price was $1,953.60 on , adjusted for stock splits. At $3.30 as of , it is 99.8% below that record.
Has ACST stock ever split?
Yes, three times: 1-for-10 on ; 1-for-8 on ; 1-for-6 on .
How has ACST stock performed?
Including dividends and measured to the last price on , ACST has returned +14.2% so far this year and +37.5% over the past year, and −96.8% over five years (−49.9% a year). Past performance doesn’t predict future returns.
What sector and industry is Acasti Pharma in?
Acasti Pharma is in the Healthcare sector and the Biotechnology industry, and is headquartered in Quebec, Canada.
What exchange does ACST trade on?
Acasti Pharma trades on the Nasdaq under the ticker symbol ACST. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.